All affected individuals known so far have moderate-to-severe DD/ID. Additional features epilepsy, muscular hypotonia, spasticity, feeding difficulties and movement disorders.
All affected individuals known so far have moderate-to-severe DD/ID. Additional features epilepsy, muscular hypotonia, spasticity, feeding difficulties and movement disorders.